ArticleBrain communications2025
Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- User-centered design and formative evaluation of a gait dashboard for multidimensional walking assessment in multiple sclerosis.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mobility impairment is a hallmark of disease worsening in multiple sclerosis (MS), yet its phenotypic diversity and pathophysiology mechanisms are not completely understood. Conventional gait assessments often rely on subjective clinical measures, which may not fully capture the complexity of gait abnormalities. The integration of advanced quantitative gait analysis, quantitative from MRI, and machine learning (ML) may reveal unique mobility phenotypes, potentially reflecting underlying disease mechanisms and heterogeneity. In this study, we aimed to identify and characterize mobility phenotypes among people with MS (pwMS) using a mixed approach with spatiotemporal gait parameters and MRI-derived features, supported by unsupervised ML clustering. 1026 pwMS underwent comprehensive gait assessments and quantitative MRI between 2018 and 2023. Principal component analysis was applied for dimensionality reduction and k-means clustering to identify distinct phenotypes. Clusters were compared using demographic, clinical, and MRI features, with statistical comparisons performed using Kruskal-Wallis and Chi-square tests. Four gait clusters were identified. Cluster 1 (faster stable, 47.8%), demonstrated the most efficient gait features and highest grey matter fractions. Cluster 4 (slow severely unstable, 7.4%) showed profound disability, shortest strides, lowest velocity, and greatest variability. Intermediate clusters 2 (slower stable, 32.3%) and 3 (moderately unstable, 12.6%) had similar velocity but differed in cadence and stride length. Cluster 3, marked by shorter steps and increased cadence, showed higher lesion burden and lower brain parenchymal fraction, suggesting emerging structural impairment and possible compensatory gait. Clinical measures aligned with these findings: unstable Clusters 3 and 4 had the highest proportion of progressive MS, worst disability scores, longest disease duration, and greatest self-reported gait impairment. Integrating quantitative MRI metrics with spatiotemporal gait analysis has the potential to phenotype clinical impairments in pwMS. ML-driven analysis identified a novel intermediate cluster, distinguished by a gait with increased cadence and shorter strides, alongside distinct MRI abnormalities. This pattern may reflect a potential adaptation within the mobility spectrum, not yet conclusively discernible by human raters but detectable through ML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.